Research Analysts Issue Forecasts for Catalent Inc’s Q2 2019 Earnings (CTLT)
Catalent Inc (NYSE:CTLT) – Equities research analysts at First Analysis issued their Q2 2019 earnings per share estimates for shares of Catalent in a research report issued on Wednesday. First Analysis analyst anticipates that the company will post earnings per share of $0.48 for the quarter. First Analysis has a “Equal Weight” rating on the stock.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to analysts’ expectations of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The business’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.
Shares of Catalent (CTLT) traded down $0.11 during trading on Thursday, hitting $40.47. 1,283,744 shares of the company’s stock traded hands, compared to its average volume of 969,020. The company has a market cap of $5,496.73, a PE ratio of 69.63, a price-to-earnings-growth ratio of 2.40 and a beta of 1.47. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87. The company has a quick ratio of 2.49, a current ratio of 2.22 and a debt-to-equity ratio of 2.66.
In related news, insider John R. Chiminski sold 181,458 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Uwe Roehrhoff bought 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The stock was bought at an average cost of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in CTLT. PNC Financial Services Group Inc. boosted its stake in Catalent by 111.5% in the 2nd quarter. PNC Financial Services Group Inc. now owns 12,838 shares of the company’s stock worth $451,000 after purchasing an additional 6,768 shares during the period. California Public Employees Retirement System boosted its stake in Catalent by 2.2% in the 2nd quarter. California Public Employees Retirement System now owns 200,800 shares of the company’s stock worth $7,048,000 after purchasing an additional 4,400 shares during the period. Advisor Group Inc. boosted its stake in Catalent by 1.3% in the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after purchasing an additional 65 shares during the period. Stifel Financial Corp boosted its stake in Catalent by 0.9% in the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after purchasing an additional 96 shares during the period. Finally, AHL Partners LLP acquired a new position in Catalent in the 2nd quarter worth $424,000. 98.86% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/09/research-analysts-issue-forecasts-for-catalent-incs-q2-2019-earnings-ctlt.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.